JPMorgan Chase & Co. Lowers Oxford Biomedica (LON:OXB) Price Target to GBX 400

Oxford Biomedica (LON:OXB - Free Report) had its target price lowered by JPMorgan Chase & Co. from GBX 490 ($6.58) to GBX 400 ($5.37) in a research note published on Tuesday morning, Marketbeat Ratings reports. The brokerage currently has a neutral rating on the biopharmaceutical company's stock.

Oxford Biomedica Price Performance

LON:OXB traded up GBX 7.50 ($0.10) during mid-day trading on Tuesday, reaching GBX 370 ($4.97). 35,244 shares of the company were exchanged, compared to its average volume of 233,013. The stock has a market cap of £393.31 million, a PE ratio of -2.75 and a beta of 1.09. The company has a quick ratio of 1.67, a current ratio of 2.35 and a debt-to-equity ratio of 166.48. Oxford Biomedica has a 12 month low of GBX 232.50 ($3.12) and a 12 month high of GBX 455 ($6.11). The company has a fifty day moving average of GBX 324.10 and a 200 day moving average of GBX 334.55.

Insider Activity

In other news, insider Heather Preston acquired 11,389 shares of Oxford Biomedica stock in a transaction that occurred on Tuesday, June 17th. The shares were acquired at an average price of GBX 324 ($4.35) per share, with a total value of £36,900.36 ($49,550.64). Company insiders own 21.17% of the company's stock.

About Oxford Biomedica

Oxford Biomedica LSE: OXB is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies.